REPLReplimune Group, Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 20895
Ticker: REPL
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2018-07-20
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: REPL

Detail

Enriched 2026-08-14 20:47

Market cap: $1,428,408,029.64
Shares outstanding (class): 84,026,071
Shares outstanding (weighted): 93,727,561
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 465
Location: WOBURN, MA
Homepage: https://www.replimune.com
Description: Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Market cap and share counts drift.

Funds holding this security

92 funds · 92 positions · $125.89M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$18.46M	0.14%	2,413,329 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$16.82M	0.23%	2,198,386 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$14.14M	0.00%	1,848,304 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$13.25M	0.02%	1,732,293 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$12.24M	0.15%	1,599,648 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$10.92M	0.10%	1,427,764 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$6.49M	0.01%	848,759 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$4.64M	0.04%	606,216 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$4.37M	0.05%	570,930 NS	FIGI
Fidelity Enhanced Small Cap ETF Fidelity Covington Trust	FESM	$3.78M	0.09%	494,413 NS	FIGI
T. Rowe Price Small-Mid Cap ETF T. Rowe Price Exchange-Traded Funds, Inc.	TMSL	$1.89M	0.12%	246,899 NS	FIGI
JPMorgan Small Cap Value Fund JPMorgan Trust II	—	$1.69M	0.15%	220,486 NS	FIGI
T.Rowe Price Small Cap Growth Portfolio Brighthouse Funds Trust II	—	$1.47M	0.14%	191,701 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$1.39M	0.11%	181,487 NS	FIGI
T. Rowe Price Integrated U.S. Small-Mid Cap Cor… T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$1.25M	0.09%	162,947 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERREPL
FIGI_COMPOSITEBBG00L8Z22R1
FIGI_SHARE_CLASSBBG00L8Z22S0
CIK0001737953
ISINUS76029N1063
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.